Jubilant Pharmova files SEBI SAST disclosure for share acquisition by Bhartia family trustees

What Jubilant Pharmova announced

Jubilant Pharmova Ltd (BSE: 530019) disclosed on 19 June 2026 that it has received a filing under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing relates to share acquisitions made by HSB Trustee Company Pvt Ltd and HS Trustee Company Pvt Ltd (jointly acting as trustees for the Hari Shanker Bhartia Family Trust) and SPB Trustee Company Pvt Ltd and SS Trustee Company Pvt Ltd (jointly acting as trustees for the Shyam Sunder Bhartia Family Trust).

The announcement does not provide the number of shares acquired, the price paid, or the percentage of total share capital that the trustees now hold. It merely satisfies the statutory requirement to inform the market that a substantial acquisition is in progress.

Parties involved and their role

• HSB Trustee Company Pvt Ltd & HS Trustee Company Pvt Ltd – appointed trustees for the Hari Shanker Bhartia Family Trust.
• SPB Trustee Company Pvt Ltd & SS Trustee Company Pvt Ltd – appointed trustees for the Shyam Sunder Bhartia Family Trust.

Both sets of trustees are acting on behalf of the respective family trusts, which are the ultimate beneficial owners of the shares being acquired. The filing does not disclose whether the trustees are acquiring the shares for investment, voting control, or any other purpose.

Regulatory framework (Regulation 31)

Regulation 31(1) requires any person or entity that acquires more than 1% of the voting share capital of a listed company to disclose the acquisition to the stock exchange within two working days. Regulation 31(2) mandates that the acquirer must also file a detailed statement with SEBI, outlining the purpose of the acquisition, the source of funds, and any agreements that may affect the company's control.

The filing therefore satisfies the immediate disclosure obligation. If the cumulative shareholding of the trustees crosses the 25% threshold, the acquirer would be required to make an open offer to the remaining shareholders under the Takeover Code.

Key facts at a glance

Why this matters for investors

• Potential dilution or control shift – If the trustees increase their holding beyond 25%, a mandatory open offer could be triggered, affecting the free‑float and possibly the governance of Jubilant Pharmova.
• Further disclosures expected – SEBI requires a follow‑up statement within 30 days detailing the exact share count, price paid, and source of funds. Investors should watch for that subsequent filing.
• No immediate financial impact disclosed – The current filing does not reveal any cash outflow, debt issuance, or related party transaction that would affect the company’s balance sheet.

Conclusion

Jubilant Pharmova has complied with SEBI’s immediate disclosure rules by reporting that trustees of two Bhartia family trusts are acquiring shares in the company. The filing does not disclose the size or purpose of the acquisition, and further details are expected in a subsequent SEBI‑mandated statement. Investors should monitor upcoming disclosures to assess whether the acquisition will lead to a change in control or trigger a mandatory open offer.